A phase II, multicenter, open-label study of [fam-] trastuzumab deruxtecan (DS 8201a) in subjects with HER2-expressing gastric cancer.

被引：1
|
作者：
Shitara, Kohei
Bang, Yung-Jue
Chung, Hyun Cheol
Yabusaki, Hiroshi
Iwasa, Satoru
Sakai, Daisuke
Muro, Kei
Sugimoto, Naotoshi
Yasui, Hisateru
Gamoh, Makio
Murakawa, Yasuko
Negoro, Yuji
Nishina, Tomohiro
Hosaka, Hisashi
Omuro, Yasushi
Kawaguchi, Yoshinori
Sugihara, Masahiro
Saito, Kaku
Dalal, Rita
Yamaguchi, Kensei
机构：
[1] Natl Canc Ctr Hosp East, Chiba, Japan
[2] Seoul Natl Univ Hosp, Seoul, South Korea
[3] Yonsei Canc Ctr, Seoul, South Korea
[4] Niigata Canc Ctr Hosp, Niigata, Japan
[5] Natl Canc Ctr, Dept Expt Therapeut, Tokyo, Japan
[6] Osaka Univ Hosp, Osaka, Japan
[7] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan
[8] Osaka Int Canc Inst, Osaka, Japan
[9] Kobe City Med Ctr Gen Hosp, Kobe, Hyogo, Japan
[10] Osaki Citizen Hosp, Osaki, Japan
[11] Miyagi Canc Ctr, Natori, Miyagi, Japan
[12] Kochi Hlth Sci Ctr, Kochi, Japan
[13] Natl Hosp Org Shikoku Canc Ctr, Matsuyama, Ehime, Japan
[14] Gunma Prefectural Canc Ctr, Ota, Japan
[15] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan
[16] Daiichi Sankyo Co Ltd, Tokyo, Japan
[17] Daiichi Sankyo Inc, Basking Ridge, NJ USA
[18] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期
关键词：
D O I：
10.1200/JCO.2019.37.4_suppl.TPS180
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS180
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts.
    Iwata, Hiroji
    Tamura, Kenji
    Doi, Toshihiko
    Tsurutani, Junji
    Modi, Shanu
    Park, Haeseong
    Krop, Ian E.
    Sagara, Yasuaki
    Redfern, Charles H.
    Murthy, Rashmi Krishna
    Redman, Rebecca A.
    Shitara, Kohei
    Fujisaki, Yoshihiko
    Sugihara, Masahiro
    Zhang, Lin
    Shahidi, Javad
    Yver, Antoine
    Takahashi, Shunji
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [32] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: A randomized, phase 2, multicenter, open-label study (DESTINY-Gastric01)
    Yamaguchi, K.
    Bang, Y.
    Iwasa, S.
    Sugimoto, N.
    Ryu, M.
    Sakai, D.
    Chung, H.
    Kawakami, H.
    Yabusaki, H.
    Lee, J.
    Saito, K.
    Kawaguchi, Y.
    Kamio, T.
    Kojima, A.
    Sugihara, M.
    Shitara, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S235 - S235
  • [33] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study
    Yamaguchi, K.
    Bang, Y-J.
    Iwasa, S.
    Sugimoto, N.
    Ryu, M-H.
    Sakai, D.
    Chung, H. C.
    Kawakami, H.
    Yabusaki, H.
    Lee, J.
    Saito, K.
    Kawaguchi, Y.
    Kamio, T.
    Kojima, A.
    Sugihara, M.
    Shitara, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S899 - S900
  • [34] Autophagy modulates intracellular dynamics of [fam-]trastuzumab deruxtecan (DS-8201a), a novel HER2 antibody-drug conjugate (HER2-ADC)
    Abe, Manabu
    Nagata, Motoko
    Koyama, Kumiko
    Yasuda, Satoru
    Hirata, Tsuyoshi
    Kuwahara, Yusuke
    Inaki, Koichiro
    Kasanuki, Naomi
    Minami, Megumi
    Hagihara, Katsunobu
    Wakita, Kenichi
    Slosberg, Eric
    Murakami, Masato
    CANCER RESEARCH, 2019, 79 (13)
  • [35] An open-label, multicenter, phase II study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) part 2
    Lee, J-Y
    Makker, V.
    Oaknin, A.
    Oh, D-Y
    Anoka, C.
    Jung, L.
    Simoes, J.
    Puvvada, S. D.
    Meric-Bernstam, F.
    ANNALS OF ONCOLOGY, 2024, 35 : S1553 - S1553
  • [36] An open-label, multicenter, phase II study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) part 2
    Lee, J-Y.
    Makker, V.
    Oaknin, A.
    Oh, D-y.
    Anoka, C.
    Jung, L.
    Simoes, J.
    Puvvada, S. D.
    Meric-Bernstam, F.
    ANNALS OF ONCOLOGY, 2024, 35
  • [37] EVALUATION OF DRUG-DRUG INTERACTIONS (DDI) BETWEEN OATP1B/CYP3A INHIBITORS AND [FAM-] TRASTUZUMAB DERUXTECAN (T-DXD, DS 8201) IN HER2-EXPRESSING SOLID TUMORS.
    Kamiyama, E.
    Garimella, T.
    Bang, Y.
    Takahashi, S.
    LaCreta, F.
    Ishizuka, H.
    Abutarif, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S69 - S69
  • [38] A phase Ib/II, multicenter, open-label, dose-escalation, and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd, DS-8201) monotherapy and combinations in patients with HER2-overexpressing gastric cancer (DESTINY-Gastric03).
    Janjigian, Yelena Y.
    Viglianti, Natasha
    Liu, Feng
    Mendoza-Naranjo, Ariadna
    Croydon, Liz
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [39] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial).
    Ohba, Akihiro
    Morizane, Chigusa
    Kawamoto, Yasuyuki
    Komatsu, Yoshito
    Ueno, Makoto
    Kobayashi, Satoshi
    Ikeda, Masafumi
    Sasaki, Mitsuhito
    Furuse, Junji
    Okano, Naohiro
    Hiraoka, Nobuyoshi
    Yoshida, Hiroshi
    Kuchiba, Aya
    Sadachi, Ryo
    Nakamura, Kenichi
    Matsui, Naoko
    Nakamura, Yoshiaki
    Okamoto, Wataru
    Yoshino, Takayuki
    Okusaka, Takuji
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [40] A phase Ib/II, multicenter, open-label, dose-escalation and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd; DS8201) monotherapy and combinations in patients with HER2-overexpressing gastric cancer (DESTINY-Gastric03)
    Janjigian, Y. Y.
    Viglianti, N.
    Liu, F.
    Mendoza-Naranjo, A.
    Puvvada, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S930 - S931
12345